Hereby, they were able to define in addition to 8 established AML subsets three new subtypes which included AML with spliceosome mutations, AML with Tumor Protein 53 (TP53) mutations and AML with IDH2R172 mutations [32]. Here, TP53 is linked to acute myeloid leukemia.